Poor
Not Aligned
Patient Risk:
Moderate
Summary
Substantial portions of the claims are either unsupported or only weakly supported by the provided label excerpts. Multiple major efficacy/indication statements (e.g., invasive aspergillosis, candidemia/invasive candidiasis, esophageal candidiasis) and several safety-related claims (e.g., liver toxicity, visual disturbances, monitoring instruction, 'common side effects') lack support in the supplied label section mapping, resulting in overall poor label adherence.
Category Scores
Accurate Statements
Voriconazole is available as an oral suspension formulation.
Supported by 11 DESCRIPTION (VFEND for Oral Suspension powder reconstitution).
Voriconazole is available as an intravenous (IV) formulation.
Supported by 11 DESCRIPTION (VFEND I.V. lyophilized powder for IV infusion).
Voriconazole belongs to the triazole class of antifungal agents.
Supported by 11 DESCRIPTION (chemical designation includes triazol-1-yl).
Voriconazole carries a risk of drug interactions.
Supported by 5.13 Clinically Significant Drug Interactions and 4 Contraindications references.
Risks associated with voriconazole include severe skin reactions.
Supported by 5.5 Severe Cutaneous Adverse Reactions (SCARs such as SJS/TEN/DRESS).
Risks associated with voriconazole include interactions with other medications.
Supported by 5.13 Clinically Significant Drug Interactions and 4 Contraindications references.
Unsupported Statements
Voriconazole is used for invasive aspergillosis.
Marked absent from the provided label mapping for 1 INDICATIONS AND USAGE; no supporting citation in the supplied excerpts.
Voriconazole is used for candidemia (invasive candidiasis).
Marked absent from the provided label mapping for 1 INDICATIONS AND USAGE; no supporting citation in the supplied excerpts.
Voriconazole is used for esophageal candidiasis.
Marked absent from the provided label mapping for 1 INDICATIONS AND USAGE; no supporting citation in the supplied excerpts.
Voriconazole is particularly effective against infections caused by Candida species (including fluconazole-resistant strains).
Provided mapping indicates absent label support; additionally the fluconazole-resistant specificity is not supported by the supplied excerpts.
Voriconazole works by inhibiting the enzyme lanosterol 14-alpha-demethylase.
Marked absent from the provided label mapping.
Lanosterol 14-alpha-demethylase is essential for ergosterol synthesis.
Marked absent from the provided label mapping.
Ergosterol is a vital component of fungal cell membranes.
Marked absent from the provided label mapping.
Depletion of ergosterol disrupts fungal cell membrane integrity and function.
Marked absent from the provided label mapping.
Depletion of ergosterol leads to fungal cell death.
Marked absent from the provided label mapping.
Generic versions of voriconazole are available.
No label citation provided; marked absent from provided mapping.
The availability of generic versions of voriconazole typically follows the expiry of relevant patents and regulatory approvals.
No label citation provided; non-label policy/legal statement and marked absent from provided mapping.
Common side effects of voriconazole include visual disturbances such as blurred vision.
Marked absent from provided label mapping; the cited sections are not shown in the provided excerpts to support this exact 'common side effects' claim.
Common side effects of voriconazole include changes in color perception.
Marked absent from provided label mapping.
Common side effects of voriconazole include rash.
Marked absent from provided label mapping.
Common side effects of voriconazole include nausea.
Marked absent from provided label mapping.
Common side effects of voriconazole include vomiting.
Marked absent from provided label mapping.
Common side effects of voriconazole include diarrhea.
Marked absent from provided label mapping.
Common side effects of voriconazole include headache.
Marked absent from provided label mapping.
Common side effects of voriconazole include liver enzyme elevations.
Marked absent from provided label mapping.
Voriconazole is a broad-spectrum antifungal agent.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Voriconazole generally has a broader spectrum of activity than older azoles like fluconazole.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Voriconazole is effective against a wider range of fungi than fluconazole.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Voriconazole is effective against many Aspergillus species that are resistant to fluconazole.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Voriconazole carries a risk of potential liver toxicity.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Risks associated with voriconazole include potential liver damage.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Risks associated with voriconazole include visual disturbances.
Marked absent from provided label mapping; no supporting citation in supplied excerpts.
Patients taking voriconazole require close monitoring by a healthcare professional.
Marked absent from provided label mapping for the specified counseling instruction.
Contradictions
Important Omissions
Any dose, regimen, titration, or administration instructions aligned to the label (e.g., preparation/dilution specifics) are not evaluated because the provided extracted claims contain no dosing details.
Importance:
None
Safety Assessment
Potential Patient Risk:
Moderate
Several efficacy and safety-related claims are asserted without support in the provided label mapping, including liver-toxicity/liver-damage risk and visual disturbances. Additionally, 'common side effects' statements appear unsupported by the provided excerpts, which can mislead about expected adverse effects and monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Large number of claims are marked unsupported/absent or only partially supported by the supplied label excerpts, especially for indications and safety/adverse effect assertions.
Suggested Improvement
Restrict statements to what is supported by the provided label sections (e.g., dosage form availability from 11 DESCRIPTION, SCAR risk from 5.5, interaction risk from 5.13). Remove or rephrase unsupported mechanistic, efficacy/indication, generic availability, and 'common side effects/monitoring' claims unless supported by additional label text not included in the supplied excerpts.